S-14001(S-14001) - _专利_临床

概要

基本信息

药物类型

未知

别名

靶点-

作用机制-

治疗领域

其他疾病

在研适应症-

非在研适应症

重度抑郁症

原研机构

Les Laboratoires Servier SAS

在研机构-

非在研机构

Les Laboratoires Servier SAS

最高研发阶段无进展临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 S-14001 相关的临床结果

登录后查看更多信息

100 项与 S-14001 相关的转化医学

登录后查看更多信息

100 项与 S-14001 相关的专利（医药）

登录后查看更多信息

1

项与 S-14001 相关的文献（医药）

1992-09-01·General Pharmacology: The Vascular System

Effects of S14001 on adrenergic neuroeffector interaction in isolated canine saphenous veins

Article

作者: Yuko Hoshino ; Helen Hughes ; Tony J. Verbeuren ; Paul M. Vanhoutte

1. The effects of (S) fluoro-6 (morpholinyl-2 methoxy)-8-tetrahydro-1,2,3,4 quinoleine (S14001) on adrenergic neurotransmission in isolated canine saphenous veins were investigated in experiments which measured the accumulation, overflow and metabolism of 3H-norepinephrine. 2. S14001 inhibited the accumulation of total tritium (3H-norepinephrine and 3H-metabolites of norepinephrine) in a concentration-dependent manner. 3. Under basal conditions, S14001 increased tension and basal effiux of total tritium; the latter consisted predominantly of 3H-DOPEG. The increases in these parameters were not inhibited by desmethylimipramine (DMI). 4. During electrical stimulation, S14001 increased the contraction and overflow of total tritium; the latter consisted predominantly of 3H-DOPEG. The increases in these parameters were inhibited by DMI. 5. These experiments suggest that S14001 has dual effects on adrenergic neurotransmission in the canine saphenous vein: (a) an inhibitory action on the neuronal accumulation; and (b) a pharmacological displacement of the transmitter from adrenergic nerve terminals.

100 项与 S-14001 相关的药物交易

登录后查看更多信息